Inclusion Criteria:

- Histologically proven gastric or gastroesophagic junction adenocarcinoma

- Measurable disease at least in a unidimensional manner. If a unique metastasis
constitutes the only disease symptom, histological confirmation will be required

- Metastatic or locally non-surgical primary gastric cancer

- Recurrent gastric cancer after local and/or systemic treatment with a post-surgical
period of at least 4 weeks, a post-adjuvant chemotherapy period or a neo-adjuvant
chemo-radiotherapy of at least 6 months

- Serum bilirubin< 2 mg/dl

- Serum creatinine < or =to 2 times normal superior limit

- Absolute neutrophil count > or =to 2000/dl

- Platelet count > or =to 100000/dl

- Hemoglobin > or =to 10 g/dl

- AST/ALT < or =to 2.5 times normal superior institutional limit

- Alkaline phosphatase < or =to 5 times the normal superior institutional limit

- Age > 18 years

- Performance Status ECOG 0-2

- Written informed consent signed and dated

Exclusion Criteria:

- Symptomatic sensory peripheral neuropathy

- Uncontrolled concomitant disease.(e.g. severe diabetes mellitus, arterial
hypertension)

- Any other malignancy diagnosed within 5 years previous to the gastric cancer, with
the exception of " in situ " cervix carcinoma or non-melanoma skin cancer

- Concomitant anti-tumoral treatment

- Cerebral metastases

- Unstable heart disease, even though under treatment

- Myocardial infarction within the last 6 months

- Pregnancy or nursing (or women in reproductive life without adequate contraception)

- Significant neurological or psychiatric disorders